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Copeptin as a marker of outcome after
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Janneke Horn7, Jesper Kjaergaard6, Michael Kuiper8, Homa Rafi Nikoukhah9, Pascal Stammet10, Johan Undén11,
Michael Jaeger Wanscher12, Matt Wise13, Hans Friberg1 and Niklas Nielsen2
Abstract
Background: Arginine vasopressin has complex actions in critically ill patients, involving vasoregulatory status,
plasma volume, and cortisol levels. Copeptin, a surrogate marker for arginine vasopressin, has shown promising
prognostic features in small observational studies and is used clinically for early rule out of acute coronary
syndrome. The objective of this study was to explore the association between early measurements of copeptin,
circulatory status, and short-term survival after out-of-hospital cardiac arrest.
Methods: Serial blood samples were collected at 24, 48, and 72 h as part of the target temperature management at
33 °C versus 36 °C after cardiac arrest trial, an international multicenter randomized trial where unconscious survivors
after out-of-hospital cardiac arrest were allocated to an intervention of 33 or 36 °C for 24 h. Primary outcome was
30-day survival with secondary endpoints circulatory cause of death and cardiovascular deterioration composite; in
addition, we examined the correlation with extended the cardiovascular sequential organ failure assessment
(eCvSOFA) score.
Results: Six hundred ninety patients were included in the analyses, of whom 203 (30.3%) developed cardiovascular
deterioration within 24 h, and 273 (39.6%) died within 30 days. Copeptin measured at 24 h was found to be independently
associated with 30-day survival, hazard ratio 1.17 [1.06–1.28], p= 0.001; circulatory cause of death, odds ratio 1.03 [1.01–1.04],
p= 0.001; and cardiovascular deterioration composite, odds ratio of 1.05 [1.02–1.08], p< 0.001. Copeptin at 24 h was
correlated with eCvSOFA score with rho 0.19 [0.12–0.27], p< 0.001.
Conclusion: Copeptin is an independent marker of severity of the post cardiac arrest syndrome, partially related to
circulatory failure.
Trial registration: Clinical Trials, NCT01020916. Registered November 26, 2009.
Keywords: Humans, Copeptin, Arginine vasopressin, AVP protein human, Out-of hospital cardiac arrest, Biomarkers, Critical
illness, Prognosis, Survivors
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Introduction
Hypoxic ischemic encephalopathy (HIE) is the major de-
terminant of outcome after out-of-hospital cardiac arrest
(OHCA) [1]. Existing prognostication models are tar-
geted at neurologic functional outcome. Death is bi-
phasic after OHCA with early death (1–3 days) to a large
degree related to circulatory failure, while later death (>
3 days) is mainly related to withdrawal of life-sustaining
therapy (WLST) due to assumed severe HIE [2]. Patients
with a presumed high risk of circulatory-related death
may therefore benefit from extended hemodynamic
monitoring and support. This is particularly relevant for
patients without signs of severe HIE and a potential
good long-term outcome. A risk stratification model ad-
dressing this topic has recently been presented but did
not include the use of biomarkers [3].
Arginine vasopressin (AVP) is a peptide hormone re-
leased from the posterior pituitary gland that increases
solute-free water reabsorption in the renal tubules and
systemic vascular resistance by constricting selected ar-
terioles. Elevated AVP levels have been shown to correl-
ate with shock [4] and cardiovascular failure [5–7].
Measurement of AVP is challenging because of its short
half-life, but it can be replaced by measurement of
copeptin (also known as CT-proAVP), the C-terminal
proteolytic product of the pre-pro-hormone of AVP.
Copeptin has shown to be a reliable surrogate biomarker
of vasopressin [8], and levels are significantly increased
at hospital admission in patients with acute coronary
syndrome [9]. Also, high copeptin levels are associated
with risk of death in patients with cardiovascular failure
[10, 11] while low levels have been implemented in clin-
ical practice to rule out non-ST-segment acute myocar-
dial infarction [9, 12]. Furthermore, copeptin has been
suggested as a promising prognostic biomarker after
OHCA [13–16]. It is unknown whether the prognostic
capabilities of AVP/copeptin are related to cardiovascu-
lar failure alone or if copeptin is merely a marker of dis-
ease severity. The aim of this exploratory study was to
investigate the relationship between early copeptin
levels, circulatory failure, and mortality in the setting of
OHCA. We hypothesized that (1) early copeptin levels
are associated with early mortality and (2) copeptin
levels are associated with circulatory failure.
Materials and methods
Study design and setting
This is a predefined biomarker sub-study of the target
temperature management (TTM) 33 °C versus 36 °C
after out-of-hospital cardiac arrest trial [17], randomiz-
ing 950 unconscious OHCA patients to an intervention
of 33 °C or 36 °C, indicating no significant benefit of a
target temperature of 33 °C compared to 36 °C [17]. The
trial protocol was approved by ethical committees in
each participating country, and informed consent was
waived or obtained from all participants or relatives ac-
cording to national legislation, in line with the Helsinki
declaration [18].
Study population
Unconscious adult patients were included in the TTM
trial within 4 h of return of stable spontaneous circula-
tion (ROSC) after OHCA of a presumed cardiac cause.
Previous medical history was recorded without no strict
definitions. Patient hemodynamics at screening and be-
fore randomization were classified in one of three cat-
egories: 1, no shock, systolic blood pressure (SBP) > 90
mmHg; 2, moderate shock, SBP < 90 mmHg for > 30
min, or the need of supportive measures (fluid loading,
vasopressor, and/or inotropic support) to maintain SBP
> 90mmHg and/or end-organ hypoperfusion (cool ex-
tremities, urine output < 30 ml/h); and 3, severe shock,
SBP < 80mmHg in spite of supportive measures (med-
ical and mechanical) that could not be reversed within
the inclusion window. Patients in persistent severe shock
were not eligible. Of the 36 study sites, seven sites did
not participate in the biobank sub-study due to legal or
logistical reasons. This analysis included all patients alive
at 24 h with at least one recorded copeptin level during
the sampling period.
Sampling and measurements
Blood serum samples were collected at 24, 48, and 72 h
after enrolment in the study and were processed at the
study sites, aliquoted and frozen to − 80 °C before ship-
ment to the Integrated Biobank of Luxemburg. Central-
ized batch analysis of copeptin was done using immune
fluorescence with the Brahms Kryptor Compact Plus
system (Thermo Fisher Scientific Brahms, Germany),
with range of 0.7–500 pmol/L (auto dilution with upper
range of 2000 pmol/L) and functioning assay sensitivity
of 1.08 pmol/L. All serum samples with interference de-
tected by the Kryptor system were discarded. Analyses
of copeptin were made at least 6 months after trial
completion.
Outcomes
The primary outcome was incidence of death until 30
days after enrolment in the TTM trial. The secondary
endpoints were circulatory cause of death within 30 days
of cardiac arrest, as estimated from clinical data, and the
extended cardiovascular sequential organ failure assess-
ment score (eCvSOFA), a nine level sub-score of the
SOFA cardiovascular component [19]. In addition, we
devised a binary composite outcome of cardiovascular
deterioration (cardiovascular deterioration composite
(CvDC)) considered positive if the patient had an eCv-
SOFA ≥ 5 or died from circulatory cause at within ± 12 h
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of copeptin sample or if eCvSOFA score increased more
than two points within the previous 24 h.
Statistical analysis
Descriptive statistics were used to summarize the study
population. Continuous data are presented as median
with interquartile range. Differences in baseline variables
were assessed using the Mann-Whitney or the χ2 test, as
appropriate. Analyses were primarily performed on 24-h
samples of copeptin, with the secondary analyses per-
formed on serial samples (48, 72-h samples). No formal
adjustment of significance levels due to multitesting was
performed. Due to missingness in the dataset, analyses
were performed on a pooled dataset for the explanatory
models based on 20 imputations by chained equations,
using predictive mean matching for continuous variables
and logistic regression for categorical data. Because of
skewed distribution of copeptin data, log2-transformed
copeptin levels were used in Cox and logistic regression
models. All models were adjusted for TTM at 33 °C
(yes/no) and early clinical predictors of outcome accord-
ing to the TTM-score [20]: age (years), cardiac arrest at
home (yes/no), no-flow time (minutes from cardiac ar-
rest until start of chest compressions or ROSC,
Table 1 Baseline characteristics
Characteristic Patients included in sub-study
Subjects 690
Temperature intervention at 36 C, n = 690 343 (49.7)
Age, years, n = 690 65 [56–73]
Male sex, n = 690 558 (80.9)
Previous medical history
Myocardial infarction, n = 684 134 (19.6)
Ischemic heart disease, n = 683 187 (27.4)
Arrhythmia, n = 684 121 (17.7)
Arterial hypertension, n = 682 277 (40.6)
Diabetes, n = 679 100 (14.7)
Intra-arrest characteristics
Witnessed cardiac arrest, n = 687 614 (89.4)
Cardiac arrest at home, n = 690 364 (52.8)
Bystander cardiopulmonary resuscitation, n = 690 499 (72.3)
No flow time (min), n = 679 1 [0–5]
Low flow time (min), n = 679 22 [14–35]
Dose of adrenaline (mg), n = 680 2 [0–4]
ST-elevation myocardial infarction, n = 676 276 (40.8)
First monitored rhythm, n = 690
Non shockable 128 (18.6)
Shockable 542 (78.6)
Unknown 20 (2.9)
Early hospital characteristics
Moderate shock on admission, n = 686 85 (12.4)
Lactate at admission (mmol/l), n = 619 5.9 [3.2–9.3]
Admission pCO2 < 4.5 kPa, n = 645 80 (11.6)
Pupillary or corneal reflexes present on admission, n = 649 7.23 [7.13–7.31]
Admission GCSm > 1 or sedated, n = 679 308 (44.6)
Pupillary or corneal reflexes present on admission, n = 655 527 (76.4)
Extended cardiovascular SOFA score day 1, n = 673 3 [2–4]
Positive cardiovascular deterioration composite at 24 h, n = 670 203 (30.3%)
Baseline characteristics in the TTM biobank population included in the analysis. Continuous data is presented as median value with interquartile range, while
categorical data as number of subjects and percentages. n represents the total number of samples available for analysis
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whichever was first), low-flow time (minutes with chest
compressions), shockable rhythm (yes/no), use of adren-
aline during CPR (yes/no), absence of corneal and
pupillary reflexes on admission (yes/no), Glasgow coma
score motor component (mGCS) on admission > 1 or se-
dated (yes/no), admission pH, and admission PaCO2 <
4.5 kPa (yes/no). The log-rank test was used to test for
difference in 30-day survival according to copeptin levels
stratified as above or below median at the specified time
point in the biobank population and visualized in
Kaplan-Meier graphs. Adjusted hazard ratio for death
was estimated using the Cox regression of proportional
hazards model, with follow-up time censored at 30 days.
Multivariate logistic regression was performed for circu-
latory cause of death. Correlation between copeptin and
eCvSOFA-score was assessed using Spearman’s rank
order correlation. Multivariate logistic regression was
performed for CvDC.
A sensitivity analysis was performed comparing the re-
sults of a complete cases adjusted Cox regression model
for the primary endpoint at 24, 48, and 72 h with that of
the imputed model.
Statistical analysis was performed using software R (v
3.4.0) and RStudio (v 1.0.143).
Fig. 1 Copeptin levels stratified according to 30-day mortality. Box
plot illustrating difference in copeptin levels measured at 24, 48, and
72 h after cardiac arrest in survivors vs non-survivors at day 30.
Copeptin on Y-axis is on a log scale
Fig. 2 Probability of 30-day survival. Kaplan-Meier graph illustrating the probability of survival after cardiac arrest according to copeptin levels
stratified as above or below median at 24 h. Outcome was censored after 30 days. Shaded areas indicate 95% confidence interval. Survival was
significantly higher in the group with copeptin levels below median at 24 h, p < 0.001
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Results
A total of 690 patients were included in this TTM bio-
bank sub-study (Table 1). Of 2070 possible copeptin
values, 112 (5.4%) were missing, 53 (2.6%) because of
death prior to sampling (Additional file 1).
Copeptin and temperature
Differences in copeptin levels between interventions
were highest at 72 h, 33.00 [15.76–63.62] for 33 °C and
26.46 [11.37–59.28] pmol/l, for 36 °C, p = 0.049
(Additional file 2). Copeptin levels increased more be-
tween 24 h and 48 h at an intervention of 33 °C, 6.11 [−
4.25–36.96] compared to 36 °C 1.91 [− 9.51–27.38]
pmol/l, (p = 0.026), while no significant differences were
seen between 48 and 72 h. Since differences between
intervention arms were minor and our primary aim was
to test associations between copeptin and outcome, all
further analyses were performed on pooled samples.
Copeptin and mortality
Two hundred seventy-three (39.6%) patients died within
30 days. Copeptin levels were significantly lower in survi-
vors than in patients dead by day 30, at 24 h 17.19
[9.89–36.20] versus 51.14 [19.60–99.51] pmol/l, at 48 h
31.84 [15.44–59.49] versus 57.11 [24.32–102.97] pmol/l,
and at 72 h 22.19 [9.89–48.26] versus 47.37 [22.90–
101.78] pmol/l, all p values < 0.001 (Fig. 1). Crude 30-
day survival was associated with copeptin stratified as
above or below median at 24 h, p < 0.001 (Fig. 2), at 48 h,
p = 0.001, and 72 h p < 0.001 (Additional file 3). The inci-
dence of death was independently associated with log2-
transformed copeptin, hazard ratio (HR) 1.17 [1.06–
1.28], p = 0.001(Fig. 3); for samples at 24 h, significance
was lost at 48 h, p = 0.471, while 72-h samples were
trending towards significance, HR 1.11 [1.00–1.23],
p = 0.054.
Copeptin and circulatory failure
In the adjusted model, log2-transformed copeptin was
independently associated with circulatory cause of death,
at 24 h, with an odds ratio (OR) of 1.03 [1.01–1.04], p =
0.001 (Additional file 4). The Spearman rank order cor-
relation between eCvSOFA and copeptin, rho, was 0.19
[0.12–0.27] at 24 h, 0.22 [0.14–0.29] at 48 h and 0.26
[0.18–0.34] at 72 h, p < 0.001, for all time points. Log2-
transformed copeptin was independently associated with
cardiovascular deterioration with OR 1.05 [1.02–1.08],
p < 0.001 at 24 h (Fig. 4); OR 1.03 [1.00–1.05], p = 0.021
at 48 h; and OR 1.03 [1.01–1.06], p = 0.016 at 72 h.
Fig. 3 Multivariate explanatory model for short time survival. Forest plot displaying hazard ratio for death within 30 days in a multivariate Cox
proportional hazards model adjusted for log2-transformed copeptin at 24 h, age (years), adrenaline used (yes/no), admission pH, shockable
rhythm (yes/no), cardiac arrest at home (yes/no), Glasgow Coma Scale motor component (GCSm) more than 1 or sedated at admission (yes/no),
corneal or pupillary reflexes present at admission (yes/no), no flow time = time from cardiac arrest until start of chest compression or return of
spontaneous circulation, whichever comes first (min), low flow time = from start of chest compressions until return of spontaneous circulation
(min), admission arterial pCO2 below 4.5 kPa on admission (yes/no), and temperature management at 33 C after cardiac arrest (yes/no). p values
below 0.05 were considered significant
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In the sensitivity analysis, results from the Cox regres-
sion models on imputed datasets and observed data were
similar (data not shown).
Discussion
The main findings of this sub-study of the TTM trial
were that copeptin is a time sensitive, independent pre-
dictor of early mortality after OHCA, weakly associated
with cardiovascular failure.
This is to date the largest study investigating copeptin
as a marker of outcome after OHCA. Our finding that
copeptin was associated with outcome is in agreement
with previous studies [13–16, 21, 22]. Studies by Ann-
born et al. [13, 16] and Broessner et al. [14] indicate bet-
ter prognostic precision with early measurements of
copeptin which could be one reason for copeptin being
significantly associated with survival at 24 h only, in our
multivariate analysis. Previous studies have indicated a
rapid release and clearance of copeptin [23] after circula-
tory stress, and this may explain why early copeptin
levels would be more strongly associated with early mor-
tality. Copeptin was associated with temperature change,
and the multivariate analyses are adjusted for TTM, but
it cannot be ruled out that the temperature intervention
might have confounded the results of the 48 h analysis,
since the patients in the intervention group with TTM
at 33 °C were rewarmed to 37 °C between 28 and 36 h
according to the TTM trial protocol. Death before sam-
pling is a potential confounder that decreased our results
for copeptin’s association with death, as these patients
probably had high copeptin levels.
As the results of this study indicate an association be-
tween early mortality, circulatory status and circulatory
cause of death with high early copeptin levels, it seems
reasonable to expect that the exclusion of patients with
severe hemodynamic shock may have decreased the
prognostic precision of copeptin. Since exclusion due to
irreversible severe shock in the TTM trial was 2%, we
believe this effect, however, to be minor.
Copeptin was independently associated with circula-
tory endpoints and associated with early mortality in
univariate analysis at 24, 48, and 72 h, while copeptin
was independently associated with short time survival at
24 h. This might indicate copeptin to represent the com-
posite stress due to a wide array of pathologies, e.g., hyp-
oxia, shock, and infection, rather than to represent
circulatory failure alone. This is consistent with copeptin
being associated with outcome in various other settings,
Fig. 4 Multivariate explanatory model for cardiovascular deterioration composite, CvDC, at 24 h. Forest plot displaying odds ratios for a positive
cardiovascular deterioration composite (CvDC) in a multivariate logistic regression model. CvDC was considered positive if the patient had an
extended cardiovascular SOFA score (eCvSOFA) ≥ 5 or died from circulatory cause at within ± 12 h of time point or if eCvSOFA score increased
more than two points within the previous 24 h. The model was adjusted for adjusted for log2-transformed copeptin at 24 h, age (years),
adrenaline used (yes/no), admission pH, shockable rhythm (yes/no), cardiac arrest at home (yes/no), Glasgow Coma Scale motor component
(GCSm) more than 1 or sedated at admission (yes/no), corneal or pupillary reflexes present at admission (yes/no), no flow time = time from
cardiac arrest until start of chest compression or return of spontaneous circulation, whichever comes first (min), low flow time = from start of
chest compressions until return of spontaneous circulation (min), admission arterial pCO2 below 4.5 kPa on admission (yes/no), and temperature
management at 33 °C after cardiac arrest (yes/no). p values below 0.05 were considered significant
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such as pneumonia, stroke, postoperative trauma, and
traumatic brain injury [4, 24–26].
The association of copeptin with CvDC was significant
at all time points with modest ORs, which is consistent
with the low correlation with eCvSOFA. We did not ac-
count for multitesting, but since p values were consist-
ently low, we believe copeptin is a true, albeit not
clinically relevant, indicator of circulatory status. The in-
dependent association of copeptin with circulatory cause
of death at 24 h, but not 48 or 72 h, should thus be inter-
preted cautiously.
The use of copeptin as a clinical screening tool to
identify OHCA patients who might benefit from ex-
tended hemodynamic monitoring cannot be supported
by our results, primarily because copeptin is not associ-
ated with circulatory status at any clinically relevant
level. Further studies on copeptin are needed to clarify
the optimal timing of sampling, the potential value as a
marker of circulatory failure or a marker of disease se-
verity in early multivariate prognostic models, including
comparisons to other relevant biomarkers (e.g., natri-
uretic peptides, C-reactive protein, and procalcitonin).
Furthermore, more research is warranted to investigate
the complex interactions of copeptin as a marker of free
water resorption, vasopressor, and cortisol status in the
critically injured patient.
Strengths and limitations
This is a large predefined sub-study of the TTM trial in-
vestigating copeptin as a marker of severity of the post
cardiac arrest syndrome. The TTM trial had strict rules
for withdrawal of life-sustaining therapy, and all clinical
data were prospectively collected. Analyses were made
in a single laboratory, limiting the risk of inter-
laboratory assay variability, and copeptin values were an-
alyzed after trial completion, eliminating the risk of
treatment bias. Due to the limitations of an observa-
tional study, we can however only assess associations
with outcome. It cannot be ruled out that missing data
may have affected our results. The collection of blood
samples for the biobank of the TTM trial was not specif-
ically designed for this sub-study, and the initial sam-
pling of copeptin at 24 h may have been too late for
optimal assessment of associations with outcome and
circulatory derangement. Patients dying before 24 h were
excluded from our analysis, limiting our results to pa-
tients alive at 24 h; also, the exclusion of patients in
irreversible hemodynamic shock may limit the
generalizability of our results.
Conclusion
Copeptin is an independent marker of severity of the
post cardiac arrest syndrome, partially related to circula-
tory failure.
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Additional file 1. Flow chart. A, the number of patients enrolled in the
TTM-trial and included in the sub-study. B, Illustrates missing copeptin
data within 72 h.
Additional file 2. Boxplot illustrating difference in copeptin levels
measured at 24, 48, and 72 h after cardiac arrest in patients treated with
a temperature intervention at 33 C or 36 C. Copeptin on Y-axis is on a
log scale. TTM: Targeted Temperature Management.
Additional file 3. Kaplan-Meier plots according to copeptin levels
stratified as above or below median at 48, and 72 h. Shaded areas
indicate 95% confidence interval. Outcome was censored after 30 days.
Survival was significantly higher in the group with copeptin levels below
median at 48 h, p = 0.001 and 72 h, p < 0.001.
Additional file 4. Forest plot displaying odds ratios for cardiac cause of
death within 30 days of cardiac arrest in a multivariate logistic regression
mode. The model is adjusted for adjusted for: log2 transformed copeptin
at 24 h, age (years), adrenaline used (yes/no), admission pH, Shockable
rhythm (yes/no), cardiac arrest at home (yes/no), Glasgow Coma Scale
motor component (GCSm) more than 1 or sedated at admission (yes/no),
corneal or pupillary reflexes present at admission (yes/no), no flow
time = time from cardiac arrest until start of chest compression or return
of spontaneous circulation, whichever comes first (min), low flow time =
from start of chest compressions until return of spontaneous circulation
(min), admission arterial pCO2 below 4.5 kPa on admission (yes/no), and
temperature management at 33 C after cardiac arrest (yes/no). p-values
below 0.05 were considered significant.
Abbreviations
WLST: Withdrawal of life-sustaining therapy; TTM: Targeted temperature
management; SOFA: Systemic organ failure assessment; eCvSOFA: Extended
cardiovascular systemic organ failure assessment; HIE: Hypoxic ischemic
encephalopathy; OHCA: Out-of-hospital cardiac arrest; AVP: Arginine
vasopressin; CT-proAVP: C-terminal pro-arginine vasopressin (copeptin);
ROSC: Return of spontaneous circulation; SBP: Systolic blood pressure;
CvDC: Cardiovascular deterioration composite; CPC: Cerebral performance
category; mGCS: Motor component of Glasgow Coma Score; STEMI: ST-
elevation myocardial infarction; HR: Hazard ratio; OR: Odds ratio
Acknowledgements
Analyses of copeptin were made free of charge by Thermo-Fisher Scientific
Inc.
Authors’ contributions
JDü: Design and writing of manuscript, analysis/interpretation of data. MA:
Design of manuscript, analysis/interpretation of data. Substantial revision of
manuscript. TC: Interpretation of data. Substantial revision of manuscript. JDa:
Interpretation of data. Substantial revision of manuscript. YD: Interpretation
of data. Substantial revision of manuscript. CH: Interpretation of data.
Substantial revision of manuscript. JH: Interpretation of data. Substantial
revision of manuscript. JK: Interpretation of data. Substantial revision of
manuscript. MK: Interpretation of data. Substantial revision of manuscript.
HRN: Interpretation of data. Substantial revision of manuscript. PS:
Interpretation of data. Substantial revision of manuscript. JU: Interpretation of
data. Substantial revision of manuscript. MW: Interpretation of data.
Substantial revision of manuscript. MJW: Interpretation of data. Substantial
revision of manuscript. HF: Design of manuscript, analysis/interpretation of
data. Substantial revision of manuscript. NN: Design of manuscript, analysis/
interpretation of data. Substantial revision of manuscript. The authors read
and approved the final manuscript.
Authors’ information
Not applicable
Funding
Funding for the study was provided by the Swedish Research Council
(grants 134281, 296161, 286321); Swedish Heart Lung Foundation (grant
Düring et al. Critical Care          (2020) 24:185 Page 7 of 9
20090275); Arbetsmarknadens Försäkringsaktiebolag (grant 100001); Skåne
University Hospital Foundations, the Gyllenstierna-Krapperup Foundation,
and governmental funding of clinical research within the Swedish National
Health System (grants M2010/1837, M2010/1641, 353301); The County
Council of Skåne; The Swedish Society of Medicine; The Koch Foundation;
TrygFonden (Denmark); Lundbeck Foundation (R186-2015-2132), European
Clinical Research Infrastructures Network; Thelma Zoega Foundation; Stig
and Ragna Gorthon Foundation; Thure Carlsson Foundation; Hans-Gabriel
and Alice Trolle-Wachtmeister Foundation for Medical Research; Lions
Research fund Skåne; South Swedish Hospital Region Research Funds (Södra
Sjukvårdsregionen Regionalt Forskningsstöd); The Swedish Brain Foundation;
and The Torsten Söderberg foundation at the Royal Swedish Academy of
Sciences.
The funding organizations had no role in the design and conduct of the
study, collection, management, analysis, interpretation of the data,
preparation, review, approval of the manuscript, or decision to submit the
manuscript for publication. Open access funding provided by Lund
University.
Availability of data and materials
The data that support the findings of this study are available from Niklas
Nielsen, but restrictions apply to the availability of these data, which were
used under license for the current study, and so are not publicly available.
Data are however available from the authors upon reasonable request and
with permission of Niklas Nielsen.
Ethics approval and consent to participate
The TTM trial protocol was approved by ethical committees in each
participating country, and informed consent was waived or obtained from all
participants or relatives according to national legislations, in line with the
Helsinki declaration. Ethical Review Board approval, REPN Lund Dnr 2009/
324.
Consent for publication
Not applicable
Competing interests
HF: Bard Medical (lecture fees), QuickCool (scientific advisor).
HRN: Medical Director at Thermo Fisher Scientific.
YD: Funds from; National Research Fund of Luxembourg (grants # C14/BM/
8225223 and C17/BM/11613033), The Ministry of Higher Education and
Research of Luxembourg and The Heart Foundation - Daniel Wagner.
MW: BARD Medical (2009: Advisory board). BARD Medical (2018: Lecture,
accommodation and travel fees).
JK: Research on management of post cardiac arrest care supported by the
NovoNordisk Foundation (NNF17OC0028706).
Author details
1Department of Clinical Sciences, Anesthesia & Intensive care, Lund
University, Skåne University Hospital, Malmö, Sweden. 2Department of
Clinical Sciences Lund, Anesthesia & Intensive care, Lund University,
Helsingborg Hospital, Helsingborg, Sweden. 3Department of Clinical Sciences,
Neurology, Lund University, Skåne University Hospital, Lund, Sweden.
4Department of Clinical Sciences, Cardiology, Lund University, Skåne
University Hospital, Lund, Sweden. 5Cardiovascular Research Unit,
Luxembourg Institute of Health, Strassen, Luxembourg. 6Department of
Cardiology, Rigshospitalet and Dept of Clinical Medicine, University of
Copenhagen, Copenhagen, Denmark. 7Department of Intensive Care,
Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
8Department of Intensive Care, Medical Center Leeuwarden, Leeuwarden,
The Netherlands. 9Thermo Fisher Scientific, Asnières sur Seine, France.
10Medical and Health Directorate, National Fire and Rescue Corps, 1, rue
Stümper, 2557 Luxembourg, Luxembourg. 11Department of Clinical Sciences
Lund, Anesthesia & Intensive care, Lund University, Halmstad Hospital,
Halmstad, Sweden. 12Department of Cardiothorasic anesthesia, Rigshospitalet
and Dept of Clinical medicine, University of Copenhagen, Copenhagen,
Denmark. 13Adult Critical Care, University Hospital of Wales, Cardiff, UK.
Received: 14 December 2019 Accepted: 16 April 2020
References
1. Laver S, Farrow C, Turner D, Nolan J. Mode of death after admission to an
intensive care unit following cardiac arrest. Intensive Care Med. 2004;30(11):
2126–8.
2. Dragancea I, Rundgren M, Englund E, Friberg H, Cronberg T. The influence
of induced hypothermia and delayed prognostication on the mode of
death after cardiac arrest. Resuscitation. 2013;84(3):337–42.
3. Bascom KE, Dziodzio J, Vasaiwala S, Mooney M, Patel N, McPherson J,
McMullan P, Unger B, Nielsen N, Friberg H, et al. Derivation and validation
of the CREST model for very early prediction of circulatory etiology death in
patients without ST-segment-elevation myocardial infarction after cardiac
arrest. Circulation. 2018;137(3):273–82.
4. Jochberger S, Zitt M, Luckner G, Mayr VD, Wenzel V, Ulmer H, Morgenthaler
NG, Hasibeder WR, Dunser MW. Postoperative vasopressin and copeptin
levels in noncardiac surgery patients: a prospective controlled trial. Shock.
2009;31(2):132–8.
5. Kim JJ, Hyun SY, Hwang SY, Jung YB, Shin JH, Lim YS, Cho JS, Yang HJ, Lee
G. Hormonal responses upon return of spontaneous circulation after cardiac
arrest: a retrospective cohort study. Crit Care. 2011;15(1):R53.
6. Lindner KH, Haak T, Keller A, Bothner U, Lurie KG. Release of endogenous
vasopressors during and after cardiopulmonary resuscitation. Heart. 1996;
75(2):145–50.
7. Imamura T, Kinugawa K, Hatano M, Fujino T, Inaba T, Maki H, Kinoshita O,
Nawata K, Kyo S, Ono M, et al. Low cardiac output stimulates vasopressin
release in patients with stage d heart failure. Circ J. 2014;78(9):2259–67.
8. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the
measurement of copeptin, a stable peptide derived from the precursor of
vasopressin. Clin Chem. 2006;52(1):112–9.
9. Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C,
Baldus S, Sinning CR, et al. Copeptin improves early diagnosis of acute
myocardial infarction. J Am Coll Cardiol. 2010;55(19):2096–106.
10. Zhong Y, Wang R, Yan L, Lin M, Liu X, You T. Copeptin in heart failure:
review and meta-analysis. Clin Chim Acta. 2017;475:36–43.
11. Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O,
Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K, et al. C-terminal
provasopressin (copeptin) is a strong prognostic marker in patients with
heart failure after an acute myocardial infarction: results from the OPTIMAAL
study. Eur Heart J. 2009;30(10):1187–94.
12. Wildi K, Zellweger C, Twerenbold R, Jaeger C, Reichlin T, Haaf P, Faoro J,
Gimenez MR, Fischer A, Nelles B, et al. Incremental value of copeptin to
highly sensitive cardiac Troponin I for rapid rule-out of myocardial
infarction. Int J Cardiol. 2015;190:170–6.
13. Annborn M, Dankiewicz J, Nielsen N, Rundgren M, Smith JG, Hertel S, Struck
J, Friberg H. CT-proAVP (copeptin), MR-proANP and Peroxiredoxin 4 after
cardiac arrest: release profiles and correlation to outcome. Acta Anaesthesiol
Scand. 2014;58(4):428–36.
14. Broessner G, Hasslacher J, Beer R, Lackner P, Lehner GF, Harler U, Schiefecker
A, Helbok R, Pfausler B, Hammerer-Lercher A, et al. Outcome prediction and
temperature dependency of MR-proANP and Copeptin in comatose
resuscitated patients. Resuscitation. 2015;89:75–80.
15. Ostadal P, Kruger A, Zdrahalova V, Janotka M, Vondrakova D, Neuzil P,
Prucha M. Blood levels of copeptin on admission predict outcomes in out-
of-hospital cardiac arrest survivors treated with therapeutic hypothermia.
Crit Care. 2012;16(5):R187.
16. Annborn M, Nilsson F, Dankiewicz J, Rundgren M, Hertel S, Struck J,
Cronberg T, Nielsen N. The combination of biomarkers for prognostication
of long-term outcome in patients treated with mild hypothermia after out-
of-hospital cardiac arrest—a pilot study. Ther Hypothermia Temp Manag.
2016;6(2):85–90.
17. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J,
Hovdenes J, Kjaergaard J, Kuiper M, et al. Targeted temperature
management at 33 degrees C versus 36 degrees C after cardiac arrest. N
Engl J Med. 2013;369(23):2197–206.
18. Williams JR. The Declaration of Helsinki and public health. Bull World Health
Organ. 2008;86(8):650–2.
19. Annborn M, Bro-Jeppesen J, Nielsen N, Ullen S, Kjaergaard J, Hassager C,
Wanscher M, Hovdenes J, Pellis T, Pelosi P, et al. The association of targeted
temperature management at 33 and 36 degrees C with outcome in
Düring et al. Critical Care          (2020) 24:185 Page 8 of 9
patients with moderate shock on admission after out-of-hospital cardiac
arrest: a post hoc analysis of the target temperature management trial.
Intensive Care Med. 2014;40(9):1210–9.
20. Martinell L, Nielsen N, Herlitz J, Karlsson T, Horn J, Wise MP, Unden J,
Rylander C. Early predictors of poor outcome after out-of-hospital cardiac
arrest. Crit Care. 2017;21(1):96.
21. Ristagno G, Latini R, Plebani M, Zaninotto M, Vaahersalo J, Masson S, Tiainen
M, Kurola J, Gaspari F, Milani V, et al. Copeptin levels are associated with
organ dysfunction and death in the intensive care unit after out-of-hospital
cardiac arrest. Crit Care. 2015;19:132.
22. Geri G, Dumas F, Chenevier-Gobeaux C, Bougle A, Daviaud F, Morichau-
Beauchant T, Jouven X, Mira JP, Pene F, Empana JP, et al. Is copeptin level
associated with 1-year mortality after out-of-hospital cardiac arrest? Insights
from the Paris registry*. Crit Care Med. 2015;43(2):422–9.
23. D'Onofrio A, Russo V, Bianchi V, Cavallaro C, Leonardi S, De Vivo S,
Vecchione F, Rago A, Ammendola E, Tavoletta V, et al. Effects of
defibrillation shock in patients implanted with a subcutaneous defibrillator:
a biomarker study. Europace. 2018;20(FI2):f233–9.
24. Xu Q, Tian Y, Peng H, Li H. Copeptin as a biomarker for prediction of
prognosis of acute ischemic stroke and transient ischemic attack: a meta-
analysis. Hypertens Res. 2017;40(5):465–71.
25. Choi KS, Cho Y, Jang BH, Kim W, Ahn C, Lim TH, Yi HJ. Prognostic role of
copeptin after traumatic brain injury: a systematic review and meta-analysis
of observational studies. Am J Emerg Med. 2017;35(10):1444–50.
26. Viasus D, Del Rio-Pertuz G, Simonetti AF, Garcia-Vidal C, Acosta-Reyes J,
Garavito A, Carratalà J. Biomarkers for predicting short-term mortality in
community-acquired pneumonia: a systematic review and meta-analysis. J
Infect. 2016;72(3):273–82.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Düring et al. Critical Care          (2020) 24:185 Page 9 of 9
